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We estimated the proportion of persons with pandemic 
(H1N1) 2009 who were shedding infectious virus at diagno-
sis and on day 8 of illness. In households with conﬁ  rmed cas-
es, nasopharyngeal swabs were collected on all members 
and tested by PCR and virus culture. Of 47 cases conﬁ  rmed 
by PCR at <7 days of illness, virus culture was positive in 
92% (11/12) of febrile and 63% (22/35) of afebrile persons. 
Of 43 persons with PCR-conﬁ  rmed pandemic (H1N1) 2009 
from whom a second specimen was collected on day 8, 
74% remained PCR positive and 19% were culture positive. 
If the 73 symptomatic household members without PCR-
conﬁ  rmed illness are assumed to have pandemic (H1N1) 
2009, a minimum of 8% (6/73) of case-patients shed repli-
cating virus on day 8. Self-isolation only until fever abates 
appears insufﬁ  cient to limit transmission. Self-isolation for a 
week may be more effective, although some case-patients 
still would shed infectious virus.
S
ince April 2009, an inﬂ  uenza A virus, pandemic (H1N1) 
2009, has spread to most countries of the world. Wide-
spread susceptibility of persons <60 years of age may have 
facilitated rapid dissemination (1). Transmissibility of in-
ﬂ  uenza viruses depends on duration of shedding, amount of 
virus shed, and other factors that may facilitate projection 
of virus into the environment, such as coughing or sneez-
ing. Challenge studies in healthy volunteers inoculated 
with seasonal inﬂ  uenza viruses have shown that shedding 
generally coincides with symptom onset starting 1 day 
after inoculation, peaks on the second day, and generally 
ends 1 week after disease onset, on day 8 (2). Duration of 
shedding is greatly affected by age, and for seasonal in-
ﬂ  uenza viruses is longer in young children than in adults 
(3–5). Since the emergence of pandemic (H1N1) 2009, the 
recommended duration of self-isolation has varied from 
complete resolution of symptoms to 1 day after fever has 
subsided (6,7). The objective of this study was to estimate 
the proportion of pandemic (H1N1) 2009–infected persons 
shedding infectious virus 1 week after illness onset.
Methods
Study Setting
The research ethics committee of the Centre Hospi-
talier Universitaire de Québec approved the study. The 
prospective study was conducted during May 27–July 10, 
2009, in Quebec City, Quebec, Canada. All participants 
were community based. Eligible persons were members 
of households in which at least 1 person with pandemic 
(H1N1) 2009 conﬁ   rmed by reverse transcription–PCR 
(RT-PCR). Primary case-patients were either referred 
by their treating physicians or identiﬁ  ed among commu-
nity contacts of persons with laboratory-conﬁ  rmed cases 
(Figure 1). At the initial home visit, a nurse obtained writ-
ten informed consent from all household members and 
collected data for each household participant by using a 
standardized questionnaire. The questionnaire asked about 
basic sociodemographic characteristics (e.g., age, sex, oc-
cupation), presence of underlying medical conditions, 
presence of various symptoms or signs (i.e., fever, chills, 
cough, sore throat, rhinorrhea, arthralgia/myalgia, fatigue, 
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dyspnea, headache, diarrhea, or vomiting), seasonal inﬂ  u-
enza vaccination history, and social and healthcare impact 
of their illness (i.e., missed workdays or schooldays, days 
spent in bed, medical consultations, emergency department 
visits, or hospital admissions).
Nasopharyngeal Swabs and Laboratory Procedures
Nasopharyngeal (NP) secretions were collected from 
all household members, both symptomatic and asymptom-
atic, with NP swabs (Nylon Flocked Swabs; Copan Inno-
vation, Brescia, Italy) that were inserted into 3 mL of uni-
versal transport medium (Copan Innovation). Patients with 
results positive by RT-PCR for pandemic (H1N1) 2009 
before day 7 since disease onset had a second NP swab 
repeated on day 8. Persons still positive on day 8 were re-
tested on day 11.
Nucleic acids were extracted from 200 μL of speci-
men by using the QIAGEN Viral RNA Mini Kit (QIA-
GEN, Mississauga, Ontario, Canada). Initially, pandemic 
(H1N1) 2009 was detected by using a conventional RT-
PCR (pH1N1 PCR) speciﬁ  c for the hemagglutinin gene 
(8). RNA extracts from pH1N1 PCR–negative specimens 
were frozen at –80°C and, once specimen collection was 
completed, were retested by using a conventional RT-PCR 
assay for all inﬂ  uenza A viruses (matrix PCR), which has a 
higher sensitivity (9).
All samples with RT-PCR–positive results were cul-
tured on MDCK cells in shell vials containing 1 mL of me-
dia to detect replicating viruses. Vials were observed daily 
for 7 days to detect cytopathic effects. Virus cultures were 
conducted on fresh specimens if they were positive by the 
pH1N1 PCR, whereas samples positive by the convention-
al matrix PCR had undergone 1 freeze-thaw cycle. All cul-
tures showing cytopathic effects were sent to the Québec 
provincial reference laboratory for RT-PCR conﬁ  rmation 
by using the previously described pH1N1 PCR.
Statistical Analyses
We compared proportions and distributions using the 
χ2 test or Fisher exact test when appropriate. All statistical 
analyses were 2-tailed, and p values <0.05 were considered 
signiﬁ  cant.
Results
Of the 173 persons from 47 participating households, 
35 with pH1N1 PCR–conﬁ  rmed persons (index case-pa-
tients) were referred by their treating physicians. Among 
the 138 other participants (household or community con-
tacts), 73 had respiratory symptoms for <7 days at the time 
of enrolment and 32 (44%) of 73 were positive by pH1N1 
PCR (Figure 1, Table 1). Cell culture was also positive for 
97% (31/32) of these pH1N1 PCR–conﬁ  rmed cases. Of the 
32 pH1N1 PCR–conﬁ  rmed cases, 78% (25/32) had fever at 
some point since illness onset; at the time of specimen col-
lection, 94% (30/32) had cough and 34% (11/32) were still 
febrile. Specimens were retested with a matrix PCR. All re-
sults from the pH1N1 PCR–positive participants were also 
positive by matrix PCR; of those who were negative by 
pH1N1 PCR, 37% (15/41) were positive. Of the 15 partici-
pants positive by matrix PCR, 13% (2/15) were positive by 
cell culture. Of the 47 conﬁ  rmed cases (32 by pH1N1 PCR 
and 12 by matrix PCR), cell culture positivity varied from 
69% to 87% for specimens obtained within 4 days after 
symptom onset and dropped to 33%–40% for specimens 
obtained days 5 and 6 after symptom onset (Figure 2).
Of the 67 patients whose results were positive by 
pH1N1 PCR (35 case-patients initially referred by their 
physicians plus 32 detected among contacts), 62 were iden-
tiﬁ  ed <7 days after symptom onset and 43 had a second 
swab collected on day 8 (Figure 1). Of these 43 cases (core 
participants), 47% were children <10 years of age, 26% 
were 10–17 years of age, and 28% were adults (>18 years 
of age) (Table 1). On day 8, 18 (42%) were still positive 
by pH1N1 PCR, and 14 others were positive only by ma-
trix PCR, for a total of 74% (32/43) positive by any PCR 
method on day 8. (Table 2) Virus culture was positive for 
19% (8/43) of the patients: culture was positive only for 
pH1N1 PCR–positive cases (8/18, 44%) but for none of the 
cases positive only by matrix PCR. PCR and virus culture 
positivity rates did not differ among age groups (Table 2). 
Only 5% (2/43) of case-patients were still febrile on day 8, 
but 91% (39/43) were still coughing. None of the 8 patients 
who had a positive virus culture on day 8 were febrile, but 
7 (88%) were still coughing. Another swab was repeated on 
day 11 for 16 of the 18 case-patients who were positive by 
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Figure 1. Flowchart of characteristics of 173 participants in study 
of shedding of pandemic (H1N1) 2009 virus, Quebec City, Quebec, 
Canada, May 27–July 10, 2009.Contagious Period for Pandemic (H1N1) 2009
pH1N1 PCR on day 8 and 14 (88%) were still positive by 
at least 1 PCR (4 by pH1N1 PCR and 10 by matrix PCR). 
However, no specimen was positive by cell culture. On day 
11, a total of 12 (86%) of the 14 PCR–positive case-patients 
were still coughing.
Of the 73 symptomatic participants tested within 7 
days after symptom onset, 15 of the 47 PCR–positive case-
patients (in gray in Figure 1) were detected only by matrix 
PCR (2/15 cell culture positive) (Table 1). Of specimens 
positive by pH1N1 PCR, 97% (31/32) were culture posi-
tive at diagnosis, 44% (8/18) on day 8, and none on day 11 
of illness. Of those whose results were positive by matrix 
PCR, 13% (2/15) were culture positive at diagnosis, and 
none were positive on days 8 or 11 of illness. Because vi-
rus culture was much less frequently positive for specimens 
positive only by matrix PCR (2/39, 5%) than for specimens 
positive by pH1N1 PCR (39/54, 72%), the 19% virus cul-
ture positivity on day 8 among core participants (all pH1N1 
PCR positive) overestimated the true proportion positive 
at day 8. Assuming that none of the 15 case-patients with 
matrix PCR–positive results and 19% of the 32 case-pa-
tients with pH1N1 PCR–positive results would shed live 
virus on day 8, we can estimate that 6 [(19% × 32 pH1N1 
PCR positive) + (0 × 15 matrix PCR positive)] of the 47 
(13%) case-patients would still be positive by virus culture 
on day 8. If, instead, we assume that all 73 symptomatic 
participants were infected by pandemic (H1N1) 2009 and 
that positive cell culture on day 8 would be found only 
in patients positive by pH1N1 PCR, then 8% (6/73) still 
would be shedding live virus 1 week after illness onset. The 
real cell culture positivity rate on day 8 for all pandemic 
(H1N1) 2009–infected patients thus probably ranges from 
8% to 13%.
Discussion
Human challenge studies with seasonal inﬂ  uenza have 
shown that virus shedding after day 7 is rare (2), but clini-
cal studies have shown that shedding may persist beyond 
that period in some populations, such as elderly persons, 
immunocompromised patients, and children (3–5,10–12). 
In a study among hospitalized persons infected with sea-
sonal inﬂ  uenza A viruses, 54% remained positive by PCR 
beyond 7 days after symptom onset, and 29% were positive 
by cell culture (13). In another study, elderly hospitalized 
patients infected by inﬂ  uenza A (H3N2) viruses had higher 
virus loads than did outpatients, and their PCR positivity 
rate 1 week after disease onset was still high (57%) (10).
In this prospective study, the proportion of pandemic 
(H1N1) 2009–infected persons still shedding replicating 
virus on day 8 varied from 8% to 13%, with no difference 
between children and adults. None were still shedding in-
fectious virus on day 11. With seasonal inﬂ  uenza, virus 
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Table 1. Characteristics of various subgroups of participants in assessment of length of shedding of pandemic (H1N1) 2009 virus,
Quebec City, Quebec, Canada, May 27–July 10, 2009* 
Characteristic
No. (%) core 
participants,
n = 43 
Symptomatic household or community contacts tested <7 days after symptom onset 
Total no. (%), 
n = 73 
No. (%) positive by 
pH1N1 and matrix 
PCRs, n = 32 
No. (%) positive by 
matrix PCR only,  
n = 15 
No. (%) negative by 
both PCRs,  
n = 26 
Age group, y 
  <10  20 (47)  24 (33)  13 (41)  4 (27)  7 (27) 
  10–17  11 (26)  15 (21)  9 (28)  1 (7)  5 (19) 
 >18 12 (28)  34 (47)  10 (31)  10 (67)  14 (54) 
Sex
  F  24 (56)  41 (56)  17 (53)  8 (53)  16 (62) 
  M  19 (44)  32 (44)  15 (47)  7 (47)  10 (38) 
Medical condition 
  Any influenza-associated  8 (19)  15 (21)  6 (19)  4 (27)  5 (19) 
  Pulmonary disease  4 (9)  10 (14)  3 (9)  4 (27)  3 (12) 
Influenza vaccination 
  2008–2009 season  9 (21)  15 (21)  8 (25)  6 (40)  1 (4) 
Clinical Illness† 
  Fever  37 (86)  37 (51)  25 (78)  8 (53)  4 (15) 
  Cough  42 (98)  58 (79)  31 (97)  13 (87)  14 (54) 
  Sore throat  26 (60)  41 (56)  19 (59)  5 (33)  17 (65) 
  Myalgia or arthralgia  17 (40)  23 (32)  12 (38)  4 (27)  7 (27) 
  Fatigue  40 (93)  51 (70)  31 (97)  10 (67)  10 (38) 
  Headache  31 (72  45 (62)  24 (75)  9 (60)  12 (46) 
  Gastrointestinal symptoms  14 (33)  18 (25)  8 (25)  5 (33)  5 (19) 
  Fever and cough  36 (84)  35 (48)  24 (75)  8 (53)  3 (12) 
  Influenza-like illness  36 (84)  34 (47)  24 (75)  8 (53)  2 (8) 
*pH1N1 PCR, PCR for pandemic (H1N1) 2009 virus.  
†Symptoms between onset of disease and first nasopharyngeal swab. RESEARCH
shedding may be longer in children because they have less 
preexisting immunity that would limit replication than in 
adults. However, children and adults <50 years of age ap-
pear equally susceptible to infection with pandemic (H1N1) 
2009 virus, which would support our ﬁ  ndings of compara-
ble virus replication and shedding across age groups stud-
ied (1).
Our study had some limitations. First, our small sam-
ple size and study design may have limited our ability to 
directly measure culture positivity on day 8. Only a small 
number of patients had a specimen collected on day 8 and 
even fewer on day 11. In retrospect, a better design would 
have been to collect specimens from all 73 symptomatic 
household members on day 8, irrespective of the initial 
pH1N1 PCR result. That design would have enabled a 
more direct estimate of the proportion of patients who were 
culture positive on day 8, rather than the indirect approach 
we used. However, our extreme scenario (which assumes 
that all 73 symptomatic contacts were infected) provides 
the minimal positivity rate on day 8, and testing of all 73 
on day 8 could only have found a proportion equal to or 
greater than our 8% estimate.
Second, our sampling methods could have inﬂ  uenced 
positivity rates. Although collection of NP specimens with 
a ﬂ  ocked swab is one of the best methods for obtaining 
specimens to detect inﬂ  uenza, those specimens might have 
been improperly collected by the nurses. Suboptimal col-
lection of swabs would have yielded false-negative PCR 
or cell culture results, which in turn would have underesti-
mated the proportion of patients shedding virus on day 8.
Third, PCR testing with the matrix PCR was con-
ducted retrospectively on frozen specimens, and only 5% 
of those were positive by virus culture. A greater propor-
tion of virus culture specimens might have been positive if 
those specimens had been processed immediately instead 
of going through a freeze-thaw cycle (14). Moreover, our 
study included only ambulatory patients ,whereas studies 
of seasonal inﬂ  uenza that include hospitalized or immuno-
compromised persons show prolonged shedding, contribut-
ing to the impression that our ﬁ  ndings most likely under-
estimate the true proportion of case-patients still shedding 
virus on day 8. The strengths of our study include its pro-
spective design in a family setting and its use of various 
methods, including 2 PCR assays and virus culture, to de-
tect pandemic (H1N1) 2009.
Our results are consistent with other reports of virus 
shedding in pandemic (H1N1) 2009–infected patients. In 
Singapore, among 70 pandemic (H1N1) 2009–infected pa-
tients treated with oseltamivir and swabbed daily until virus 
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Figure 2. Positive results by PCR and culture for inﬂ  uenza A and 
pandemic (H1N1) 2009 virus (pH1N1) in 47 household contacts 
with laboratory-conﬁ  rmed  inﬂ   uenza, by delay between day of 
symptom onset and day of ﬁ   rst swab collection, Quebec City, 
Quebec, Canada, May 27–July 10, 2009.
Table 2. PCR and virus culture positivity on days 8 and 11 of illness, by age group, Quebec City, Quebec, Canada, May 27–July 10,
2009*
Time after illness onset 
Age group, no. (%) 
Total no. (%)  p value  0–9 y  10–17 y  >18 y 
Day 8 of illness (2nd swab)  n = 20  n = 11  n = 12  n = 43 
  pH1N1 PCR–positive specimen  10/20 (50)  3/11 (27)  5/12 (42)  18/43 (42)  0.43
    Culture positive on pH1N1 PCR–positive specimen  5/10 (50)  1/3 (33)  2/5 (40)  8/18 (44)  1.00
  Matrix PCR positive  5/10 (50)  6/8 (75)  3/7 (43)  14/25 (56)  0.53
    Culture positive on matrix PCR–positive specimen  0/5 0/6 0/3 0/14 –
  Any PCR positive  15/20 (75)  9/11 (82)  8/12 (67)  32/43 (74)  0.82
    Culture positive on any PCR–positive specimen  5/15 (33)  1/9 (11)  2/8 (25)  8/32 (25)  0.51
Day 11 of illness (3rd swab)  n = 8  n = 3  n = 5  n = 16 
  pH1N1 PCR–positive specimen  3/8 (38)  0/3 1/5 (20)  4/16 (25)  0.77
    Culture positive on pH1N1 PCR–positive specimen  0/3 0/0 0/1 0/4 –
  Matrix PCR–positive specimen  4/5 (80)  3/3 (100)  3/4 (75)  10/12 (83)  1.00
    Culture positive on matrix PCR positive–specimen  0/4 0/3 0/3 0/10 –
  Any PCR positive–specimen  7/8 (88)  3/3 (100)  4/5 (80)  14/16 (88)  1.00
    Culture positive on any PCR positive–specimen  0/7 0/3 0/4 0/14 –
*pH1N1 PCR, PCR for pandemic (H1N1) 2009 virus. Contagious Period for Pandemic (H1N1) 2009
clearance, 37% were PCR positive on day 7 of their illness 
and 9% on day 10 (15). No virus culture was performed 
in that study, so we cannot estimate the proportion of pa-
tients shedding infectious virus at these time points. How-
ever, even with oseltamivir treatment, the positivity rate by 
pH1N1 PCR on day 7 was similar to our own (42%) on day 
8, and we can thus infer that the cell culture positivity rates 
also would be similar. In China, among 421 patients with 
serial swabs tested by real-time PCR but not cell culture, 
the median time from onset of disease to negative test result 
by real-time PCR was 6 days (range 1–17 days), indicating 
that 50% of patients were shedding virus >6 days (16).
 A study conducted by Witkop et al. during a pan-
demic (H1N1) 2009 outbreak at the US Air Force Acad-
emy showed that 29% (31/106) of afebrile patients and 
19% (11/58) of patients who had been symptom-free for 
24 hours still shed viable pandemic (H1N1) 2009 virus. In 
their study, 24% of 29 swabs collected on day 7 and 13% 
of the 16 swabs collected on day 8 of illness were culture 
positive, despite the large proportion of patients prescribed 
antiviral drugs (17).
No deﬁ  nitive test is available for assessing the real 
contagiousness of a patient. The presence of replicating, 
and therefore infectious, inﬂ  uenza virus is an absolute 
prerequisite for contagiousness, but it does not necessar-
ily imply it. Contagiousness depends on many factors, 
including viral load and presence of clinical characteris-
tics contributing to spread of droplets (such as coughing, 
rhinorrea, or sneezing) and is affected by the number and 
proximity of contacts between a case-patient and a sus-
ceptible person. Nevertheless, our study raises concerns 
about current recommendations for self-isolation until 
only 24 hours after fever has subsided (6). With pandemic 
(H1N1) 2009, fever generally persists 1–4 days and may 
be absent in 6%–11% of patients (1,15). In our study, of 
the 32 pH1N1 PCR–positive household members who had 
been symptomatic for <7 days, 78% had fever at any time 
since onset of their illness, but only 34% were still fe-
brile on the day they tested positive. Nonetheless, 97% of 
specimens obtained from these patients were positive by 
cell culture. Our sample size was insufﬁ  cient to directly 
compare PCR or culture positivity by fever status or other 
symptom or severity indicator at specimen collection or 
as a component of the overall illness.
Before policy implications can directly follow from 
these ﬁ  ndings, the association of self-isolation with sub-
stantial social impact needs to be carefully weighed against 
the possible beneﬁ  ts of reducing community transmission. 
In the general population, a 1-week self-isolation period 
seems more likely to prevent transmission than does iso-
lation until fever has resolved. However, given that 8%–
13% of patients may still shed infectious virus on day 8, 
longer periods of self-isolation for persons expected to 
come into contact with vulnerable persons (e.g., pregnant 
women, newborns, or immunocompromised persons) also 
may be prudent.
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